Introduction:
Induction agents play a critical role in the early management of pediatric kidney transplant recipients, aiming to enhance graft longevity and reduce rejection rates. This study investigates the impact of induction therapies on graft function and survival in the pediatric population. Aim of this study is to compare graft outcomes at 1 year and 3year with anti thymocyte globulin versus basiliximab.
Methods:
This retrospective study reviewed 90 living-related pediatric kidney transplant recipients (<18 years) from January 2011 to December 2021. Participants were divided in two groups: ATG vs Basiliximab
Results:
At one and three years, the ATG group had median (IQR) eGFR of 46.91 (41.69–60.52) and 49.88 (42.22–62.48) ml/min, respectively, similar to the Basiliximab group, which had median eGFR of 59.30 (42.12 – 74.24) and 52.88 ((41.76–64.43) ml/min, with P-values of 0.08 and 0.417.
Biopsy proven rejection rates were comparable between the groups, with ATG at 26.4% and Basiliximab at 27% (P = 0.948)
Three-year graft survival was 85.7% in the ATG group and 90.9% in the Basiliximab group, with no statistically significant difference (P = 0.733).
Though infections were numerically more in anti thymocyte globulin group than basiliximab but were not statistically significant.
Conclusions:
In conclusion, both ATG and Basiliximab groups exhibited similar eGFR values at one and three years, with no significant differences in biopsy-proven rejection rates or three-year graft survival. This suggest comparable efficacy between ATG and Basiliximab in terms of graft function and survival. year graft survival.
I have no potential conflict of interest to disclose.
I did not use generative AI and AI-assisted technologies in the writing process.